Evidence map›Paper›PMID 32203007›Full record

Trial reportBlood transfusion = Trasfusione del sangue2020

Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease.

Denise A Lopez Domowicz, Ian Welsby, Charles R Esther, Hongmei Zhu, Robert D Marek, Grace Lee, Nirmish Shah, Jessica L Poisson, Tim J McMahon

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Blood transfusion = Trasfusione del sangue, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Pannexin 1 channels control the hemodynamic response to hypoxia by regulating OAmerican journal of physiology. Heart and circulatory physiology · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Denise A Lopez DomowiczDepartment of Pediatrics, Duke University Medical Center, Durham, NC, United States of America.
Ian WelsbyDepartment of Anesthesiology, Duke University Medical Center, Durham, NC, United States of America.
Charles R EstherDepartment of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Hongmei ZhuDepartment of Medicine, Duke University Medical Center, Durham, NC, United States of America.
Robert D MarekDepartment of Medicine, Duke University Medical Center, Durham, NC, United States of America.
Grace LeeDepartment of Medicine, Duke University Medical Center, Durham, NC, United States of America.
Nirmish ShahDepartment of Pediatrics, Duke University Medical Center, Durham, NC, United States of America.
Jessica L PoissonDepartment of Pathology, Duke University Medical Center, Durham, NC, United States of America.
Tim J McMahonDepartment of Medicine, Duke University Medical Center, Durham, NC, United States of America.
Duke Medical Center · USDuke University Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
SEPSIS-INDUCED RED CELL DYSFUNCTION (SIRD)R01GM113838 · NIGMS · WASHINGTON UNIVERSITY · PI DOCTOR, ALLAN, MARSHALL, GARLAND ROSS · 2015 to 2019
$4.0M
SNO transport regulates endothelial adhesion of RBCsI01BX003478 · VA · DURHAM VA MEDICAL CENTER · PI TIMOTHY J MCMAHON · 2017 to 2026
–
BLRD VA I01 BX003478NCATS NIH HHS UL1 TR001111NIEHS NIH HHS P30 ES010126NIGMS NIH HHS R01 GM113838
6 · The paper itself

Abstract

backgroundRed blood cell (RBC) exchange (RCE) transfusion therapy is indicated for certain patients with sickle cell disease (SCD). Although beneficial, this therapy is costly and inconvenient to patients, who may require it monthly or more often. Identification of blood and plasma biomarkers that could improve or help individualise RCE therapy is of interest. Here we examined relevant blood and plasma metabolites and biomarkers of vasoactivity and RBC fragility in a pilot study of SCD patients undergoing RCE using either standard RBC units or RBC units treated with a US Food and Drug Administration (FDA)-approved additive solution containing phosphate, inosine, pyruvate, and adenine ("PIPA"). MATERIALS AND

methodsIn this prospective, single-blind, cross-over pilot clinical trial, patients were randomised to receive either standard RBC exchange or PIPA-treated RBC exchange transfusion with each RCE session over a 6-month treatment period. Pre- and post-transfusion blood samples were obtained and analysed for RBC O

resultsRed blood cell O DISCUSSION: In summary, treatment of RBCs with PIPA prior to RCE elicited favourable or neutral changes in key metabolic and vascular biomarkers. Further study of its efficacy and safety is recommended and could ultimately serve to improve outcomes in chronically transfused SCD patients.

Indexed as

Anemia, Sickle CellBlood PreservationErythrocyte TransfusionAdultCross-Over StudiesHumansMalePilot ProjectsPlasmaProspective Studies

Identifiers

PMID32203007
PMCPMC7250688
OpenAlexW3012923295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.